Interactions between Amyloid-beta and Tau in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Alzheimer's Disease
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F14%3A10292989" target="_blank" >RIV/00064203:_____/14:10292989 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00159816:_____/14:00061045 RIV/00216208:11130/14:10292989 RIV/00023752:_____/14:43914642
Výsledek na webu
<a href="http://dx.doi.org/10.3233/JAD-132393" target="_blank" >http://dx.doi.org/10.3233/JAD-132393</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3233/JAD-132393" target="_blank" >10.3233/JAD-132393</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Interactions between Amyloid-beta and Tau in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Alzheimer's Disease
Popis výsledku v původním jazyce
Background: Despite the physiological sequestration of amyloid-beta (A beta) peptides by various carriers, interactions between peptides and protein tau appear to be pathological and involved in the development of Alzheimer's disease (AD). A recent studyreported increased A beta-tau interactions in the neurons of AD patients. Objective: We investigated the possibility that levels of A beta-tau complexes in cerebrospinal fluid could be a prospective biomarker of AD, with greater sensitivity and specificity than A beta(1-42), tau, or phospho-tau individually. Methods: By means of ELISA, we estimated levels of the complexes in 161 people (non-demented controls, people with mild cognitive impairment (MCI), probable AD or other types of dementia). Results:We found significant reductions in levels in people with MCI due to AD (down to 84.5%) or with AD (down to 80.5%) but not in other types of dementia. The sensitivity of the new biomarker to AD was 68.6%, the specificity 73.3% (compared t
Název v anglickém jazyce
Interactions between Amyloid-beta and Tau in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Alzheimer's Disease
Popis výsledku anglicky
Background: Despite the physiological sequestration of amyloid-beta (A beta) peptides by various carriers, interactions between peptides and protein tau appear to be pathological and involved in the development of Alzheimer's disease (AD). A recent studyreported increased A beta-tau interactions in the neurons of AD patients. Objective: We investigated the possibility that levels of A beta-tau complexes in cerebrospinal fluid could be a prospective biomarker of AD, with greater sensitivity and specificity than A beta(1-42), tau, or phospho-tau individually. Methods: By means of ELISA, we estimated levels of the complexes in 161 people (non-demented controls, people with mild cognitive impairment (MCI), probable AD or other types of dementia). Results:We found significant reductions in levels in people with MCI due to AD (down to 84.5%) or with AD (down to 80.5%) but not in other types of dementia. The sensitivity of the new biomarker to AD was 68.6%, the specificity 73.3% (compared t
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FH - Neurologie, neurochirurgie, neurovědy
OECD FORD obor
—
Návaznosti výsledku
Projekt
Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2014
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Journal of Alzheimer's Disease
ISSN
1387-2877
e-ISSN
—
Svazek periodika
42
Číslo periodika v rámci svazku
Supplement 3
Stát vydavatele periodika
NL - Nizozemsko
Počet stran výsledku
8
Strana od-do
"S91"-"S98"
Kód UT WoS článku
000341595800011
EID výsledku v databázi Scopus
—